Subcutaneous IGF-1 is not beneficial in 2-year ALS trial
[DOI] [PubMed] [Google Scholar] 72.Aoyama T., Hara K., Maezawa Y., Kazama K., Hashimoto I., Sawazaki S., Komori K., Tamagawa H., Tamagawa A., Kano K., et al
It's the difference between having a specialized tool for one job and having a universal repair kit that works across multiple applications
That is, CMS will exclude 340B units starting on January 1, 2026
Theoretical risks of sustained angiogenic stimulation (promoting vascular supply to undetected pathological tissue) grow proportionally with the duration of use, as cumulative VEGF upregulation exceeds the controlled, injury-localized window intended by short-cycle research protocols
Free radical protection activity